HIMS stock up 16% on Wednesday, continuing month-long gains. Novo Nordisk ends partnership, cites misleading marketing and ...

Novo Nordisk announced it is cutting ties with telehealth giant Hims & Hers Health, pulling its blockbuster drug Wegovy from the platform after accusing the company of selling “illegitimate, knockoff ...

If you suffered losses exceeding $50,000 in Hims between April 29, 2025 and June 22, 2025 and would like to discuss your ...

We can't have it both ways. If we want more cutting-edge drugs, we have to protect the property rights that make them ...

Hims & Hers Health recurring revenue grew 111% YoY, boosted by personalization and chronic care. Forecasting $2.35B revenue ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

An investigation by Democratic senators has raised concerns about conflicts of interest in telehealth companies' ties to ...

Executives and directors of Hims & Hers Health Inc., a leading telehealth company, are facing a shareholder derivative ...

Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to ...

Hims & Hers (HIMS) stock in focus as the company faces a growing number of lawsuits following Novo Nordisk's (NVO) decision ...

Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month ...

Hims & Hers Health Inc. board members and executives failed to tell shareholders that its Novo Nordisk A/S Wegovy ...